Effects of PTTG Down-regulation on Proliferation and Metastasis of the SCL-1 Cutaneous Squamous Cell Carcinoma Cell Line

  • Xia, Yong-Hua (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Li, Min (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Fu, Dan-Dan (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Xu, Su-Ling (Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Li, Zhan-Guo (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Liu, Dong (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Tian, Zhong-Wei (Department of Dermatovenereology, the First Affiliated Hospital of Xinxiang Medical University)
  • Published : 2013.11.30


Aims: To study effects of down-regulation of pituitary tumor-transforming gene (PTTG) on proliferation and metastasis ability of the SCL-1 cutaneous squamous cell carcinoma (CSCC) cell line and explore related mechanisms. Methods: SCL-1 cells were divided into 3 groups (untreated, siRNA control and PTTG siRNA). Cell proliferation assays were performed using a CCK-8 kit and proliferation and metastasis ability were analyzed using Boyden chambers. In addition, expression of MMP-2 and MMP-9 was detected by r-time qPCR and Western blotting. Results: Down-regulation of PTTG could markedly inhibit cell proliferation in SCL-1 cells, compared to untreated and control siRNA groups (P < 0.05). Real-time qPCR demonstrated that expression levels of PTTG, MMP-2 and MMP-9 in the PTTG siRNA group were 0.8%, 23.2% and 21.3% of untreated levels. Western blotting revealed that expression of PTTG, MMP-2 and MMP-9 proteins in the PTTG siRNA group was obviously down-regulated. The numbers of migrating cells ($51.38{\pm}4.71$) in the PTTG siRNA group was obviously lower than that in untreated group ($131.33{\pm}6.12$) and the control siRNA group ($127.72{\pm}5.20$) (P < 0.05), suggesting that decrease of proliferation and metastasis ability mediated by PTTG knock-down may be closely correlated with down-regulation of MMP-2 and MMP-9 expression. Conclusion: Inhibition of PTTG expression may be a new target for therapy of CSCC.


  1. Akino K, Akita S, Mizuguchi T, et al (2005). A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. J Surg Res, 129, 142-6.
  2. Bhave SL, Teknos TNPan Q (2011). Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gene Expr, 21, 143.
  3. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, et al (2003). Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg, 2003, 132-6.
  4. Chen G, Li J, Li F, et al (2004). Inhibitory effects of anti-sense pttg on malignant phenotype of human ovarian carcinoma cell line sk-ov-3. J Huazhong Univ Sci Technolog Med Sci, 24, 369-72.(In Chinease)
  5. Chollet A, Hohl D, Perrier P (2012). Risk of cutaneous squamous cell carcinomas: The role of clinical and pathological reports]. Rev Med Suisse, 8, 743.
  6. Coussens LM, Tinkle CL, Hanahan D, et al (2000). Mmp-9 supplied by bone marrow.derived cells contributes to skin carcinogenesis. Cell, 103, 481-90.
  7. Fang J, Shing Y, Wiederschain D, et al (2000). Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Ncad Sci USA, 97, 3884-9.
  8. Franchi A, Santucci M, Masini E, et al (2002). Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer, 95, 1902-10.
  9. Gelse K, Poschl E, Aigner T (2003). Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev, 55, 1531-46.
  10. Geneva, Switzerland: World Health Organization. Too Much Fun in the Sun Dangerous; Press Release WHO/40; 3 August 1999.
  11. Goh RY, Bova R, Fogarty GB (2012). Cutaneous squamous cell carcinoma metastatic to parotid-analysis of prognostic factors and treatment outcome. World J Surg Oncol, 10, 1-5.
  12. Itoh Y, Nagase H (2002). Matrix metalloproteinases in cancer. Essays Biochem, 38, 21-36.
  13. Jung CR, Yoo J, Jang YJ, et al (2006). Adenovirus-mediated transfer of sirna against pttg1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology, 43, 1042-52.
  14. Kakar SS, Malik MT (2006). Suppression of lung cancer with sirna targeting pttg. Int J Oncol, 29, 387.
  15. Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141, 52-67.
  16. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-8.
  17. London CA, Sekhon HS, Arora V, et al (2003). A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther, 10, 823-32.
  18. Moore BA, Weber RS, Prieto V, et al (2005). Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope, 115, 1561-7.
  19. Mourouzis C, Boynton A, Grant J, et al (2009). Cutaneous head and neck sccs and risk of nodal experience. J Craniomaxillofac Surg, 37, 443-7.
  20. Ondruschka C, Buhtz P, Motsch C, et al (2002). Prognostic value of MMP-2,-9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract, 198, 509-15.
  21. Patel V, Ramesh A, Traicoff JL, et al (2005). Profiling egfr activity in head and neck squamous cell carcinoma by using a novel layered membrane western blot technology. Oral Oncol, 41, 503-8.
  22. Pei L, Melmed S (1997). Isolation and characterization of a pituitary tumor-transforming gene (pttg). Mol Endocrinol, 11, 433-41.
  23. Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarker s and potential therapeutic targets in human cancer. J Clin Oncol, 27, 5287-97.
  24. Shibata Y, Haruki N, Kuwabara Y, et al (2002). Expression of pttg (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol, 32, 233-7.
  25. Solbach C, Roller M, Fellbaum C, et al (2004). PTTG mRNA expression in primary breast cancer: A prognostic marker for lymph node invasion and tumor recurrence. Breast, 13, 80-1.
  26. Urba W, Washington C, Nadiminti H (2012). Cancer of the Skin. In: Harrison's Principles of Internal Medicine (18th Edition) (Longo DL, Hause SL, Jameson JL and Loscalzo, eds.). McGraw-Hill Medical Publishing Division, New York.
  27. Woodhouse EC, Chuaqui RF, Liotta LA (1997). General mechanisms of metastasis. Cancer, 80, 1529-37.<1529::AID-CNCR2>3.0.CO;2-F
  28. Zhang X, Horwitz GA, Heaney AP, et al (1999). Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab, 84, 761-7.

Cited by

  1. Metabolomics Investigation of Cutaneous T Cell Lymphoma Based on UHPLC-QTOF/MS vol.15, pp.13, 2014,
  2. Systematical Analysis of Cutaneous Squamous Cell Carcinoma Network of microRNAs, Transcription Factors, and Target and Host Genes vol.15, pp.23, 2015,
  3. Securin promotes migration and invasion via matrix metalloproteinases in glioma cells pp.1792-1082, 2015,
  4. Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis vol.17, pp.6, 2016,